Literature DB >> 973986

The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man.

C J Roberts, L Jackson, M Halliwell, R A Branch.   

Abstract

Liver volume and the clearances of antipyrine and indocyanine green have been measured before and after administration of phenobarbitone (180 mg/day) for 3 weeks to ten healthy subjects. The measurement of liver volume by an ultrasound scanning technique yielded reproducible results which were consistent with predictions of liver size by allometric methods. Before phenobarbitone, antipyrine clearance correlated with liver volume, but there was no correlation between indocyanine green clearance and liver volume. Phenobarbitone administration increased the clearance of antipyrine significantly by 90 +/- 14% but there was no significant change in indocyanine green clearance or liver volume. After phenobarbitone the correlation between antipyrine clearance and liver volume persisted. There was no correlation between indocyanine green clearance and liver volume. These results suggest that in non-medicated subjects some of the difference in antipyrine clearance is due to difference in functional hepatic parenchymal mass and that phenobarbitone increases the drug metabolising capacity per unit of hepatic mass but not total liver size.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 973986      PMCID: PMC1428933          DOI: 10.1111/j.1365-2125.1976.tb00646.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function.

Authors:  J CAESAR; S SHALDON; L CHIANDUSSI; L GUEVARA; S SHERLOCK
Journal:  Clin Sci       Date:  1961-08       Impact factor: 6.124

2.  The use of indocyanine green for the evaluation of hepatic function and blood flow in man.

Authors:  B D WIEGAND; S G KETTERER; E RAPAPORT
Journal:  Am J Dig Dis       Date:  1960-05

3.  Indocyanine green: observations on its physical properties, plasma decay, and hepatic extraction.

Authors:  G R CHERRICK; S W STEIN; C M LEEVY; C S DAVIDSON
Journal:  J Clin Invest       Date:  1960-04       Impact factor: 14.808

4.  Quantitation of tumor volumes and response to therapy with ultrasound B-scans.

Authors:  D D Tolbert; J A Zagzebski; R A Banjavic; A L Wiley
Journal:  Radiology       Date:  1974-12       Impact factor: 11.105

5.  The stimulant effect of drugs on indocyanine green clearance by the liver.

Authors:  V Melikian; J D Eddy; A Paton
Journal:  Gut       Date:  1972-10       Impact factor: 23.059

6.  Studies on the mechanism of phenobarbital-enhanced sulfobromophthalein disappearance.

Authors:  C D Klaassen; G L Plaa
Journal:  J Pharmacol Exp Ther       Date:  1968-06       Impact factor: 4.030

7.  Determination of drug metabolizing enzymes in needle biopsies of human liver.

Authors:  B Schoene; R A Fleischmann; H Remmer; H F von Oldershausen
Journal:  Eur J Clin Pharmacol       Date:  1972-03       Impact factor: 2.953

8.  Relationship between plasma antipyrine half-lives and hepatic microsomal drug metabolism in dogs.

Authors:  E S Vesell; C J Lee; G T Passananti; C A Shively
Journal:  Pharmacology       Date:  1973       Impact factor: 2.547

9.  Effect of phenobarbitone on hepatic drug-metabolizing enzymes and urinary D-glucaric acid excretion in man.

Authors:  D S Lecamwasam; C Franklin; P Turner
Journal:  Br J Clin Pharmacol       Date:  1975-06       Impact factor: 4.335

10.  Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow.

Authors:  R A Branch; D G Shand; G R Wilkinson; A S Nies
Journal:  J Clin Invest       Date:  1974-04       Impact factor: 14.808

View more
  37 in total

Review 1.  Body surface area as a determinant of pharmacokinetics and drug dosing.

Authors:  M Sawyer; M J Ratain
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

2.  Ultrasonic measurement of liver size.

Authors:  M Homeida; C J Roberts; M Halliwell; L Jackson; A E Read
Journal:  Br Med J       Date:  1976-12-25

3.  Disposition of antipyrine in patients with extensive metastatic liver disease.

Authors:  G M Robertz-Vaupel; K D Lindecken; T Edeki; C Funke; S Belwon; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

4.  Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease.

Authors:  M Homeida; C J Roberts; M Halliwell; A E Read; R A Branch
Journal:  Gut       Date:  1979-07       Impact factor: 23.059

5.  The features of hepatic enzyme induction with glutethimide in man.

Authors:  L Jackson; M Homeida; C J Roberts
Journal:  Br J Clin Pharmacol       Date:  1978-12       Impact factor: 4.335

6.  Antipyrine disposition and liver size in the elderly.

Authors:  C G Swift; M Homeida; M Halliwell; C J Roberts
Journal:  Eur J Clin Pharmacol       Date:  1978-11-16       Impact factor: 2.953

7.  Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.

Authors:  D Fabre; F Bressolle; R Goméni; O Bouvet; A Dubois; C Raffanel; J C Gris; M Galtier
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

8.  Microsomal enzyme induction in children: the influence of carbamazepine treatment on antipyrine kinetics, 6 beta-hydroxycortisol excretion and plasma gamma-glutamyltranspeptidase activity.

Authors:  T A Moreland; B K Park; G W Rylance
Journal:  Br J Clin Pharmacol       Date:  1982-12       Impact factor: 4.335

9.  Effects of cirrhosis and ageing on the elimination and bioavailability of ranitidine.

Authors:  C J Young; T K Daneshmend; C J Roberts
Journal:  Gut       Date:  1982-10       Impact factor: 23.059

10.  Physiological and pharmacological variability in estimated hepatic blood flow in man.

Authors:  T K Daneshmend; L Jackson; C J Roberts
Journal:  Br J Clin Pharmacol       Date:  1981-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.